Vivani Medical, Inc. · NASDAQ:VANI
Vivani Medical — Q3 2024 Earnings Presentation
33 slides from Vivani Medical's earnings presentation, Nov 13, 2024
Slide 1: Disclaimers
Disclaimers The following slides and any accompanying oral presentation contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the "safe ha
Slide 2: Vivani Executive Leadership Team
Vivani Executive Leadership Team Adam Mendelsohn PhD – CEO/Director Co-founder/Co-inventor of Vivani technology
Slide 3: Vivani Medical, Inc.
Vivani Medical, Inc. An innovative, biopharmaceutical company developing a portfolio of ultra long-acting, miniature, drug implants to treat chronic diseases. NanoPortal™ platform technology enables the design of implants aimed at improving medication non-adherence and tolerability.
Slide 4: Company Pipeline
Company Pipeline If Approved, Vivani Products will Compete in Markets with Large Potential
Slide 5: Drug Implants Proprietary Platform Technology
Drug Implants Proprietary Platform Technology
Slide 6: GLP-1 (exenatide) Implant and Applicator
GLP-1 (exenatide) Implant and Applicator
Slide 7: NanoPortal: Innovative Delivery Technology Designed to Assure Adherence
NanoPortalTM:Innovative Delivery Technology Designed to assure adherence
Slide 8: Nanotubes adjusted to molecule size enable desirable release profiles
By precisely adjusting nanotubes to molecule size, interactions between drug and nanotube walls can result in desirable release profiles over time, including near constant release
Slide 9: NanoPortal delivers near-constant drug release
NanoPortal delivers near-constant / minimally-fluctuating drug release
Slide 10: NanoPortal is a Platform Technology
NanoPortalTM is a Platform Technology Broad Potential Application Can Support Portfolio of New Drug Implants
Slide 11: NanoPortal implant technology designed to avoid earlier device challenges
NanoPortal implant technology designed to avoid earlier device challenges
Slide 12: Vivani Lead Program NPM-115 High-Dose Exenatide Implant
Vivani Lead Program NPM-115 High-Dose Exenatide Implant for Chronic Weight Management
Slide 13: Lead Program NPM-115: 6-Month Exenatide Implant for Chronic Weight Management
Lead Program NPM-115: Development of 6-Month Exenatide (Glucagon-like Peptide 1 Receptor Agonist) Implant for Chronic Weight Management in Obese or Overweight Patients
Slide 14: Weight Loss Medicines Associated With Adherence Challenges
Weight Loss Medicines Associated With Adherence Challenges Recent retrospective cohort study (n=1,911) reported improved medication persistence with semaglutide of 40% after one year
Slide 15: Exenatide implant associated with comparable weight loss to semaglutide in preclinical study
Exenatide implant associated with comparable weight loss to semaglutide in preclinical study
Slide 16: Exenatide implant reduces liver fat by 82% in obese mice
Exenatide implant reduces liver fat by 82% in obese mice after 12 weeks
Slide 17: Exenatide with NanoPortal associated with durable body weight effects
Exenatide delivered with NanoPortal™ technology is associated with durable body weight effects
Slide 18: 12-week exenatide implant configuration to be studied in LIBERATE-1
In vivo and in vitro performance of 12-week exenatide implant configuration to be studied in LIBERATE-1
Slide 19: 6-Month exenatide implant preclinical proof-of-concept achieved
6-Month exenatide implant preclinical proof-of-concept achieved
Slide 20: Proposed First-in-Human Trial: LIBERATE-1
Proposed First-in-Human Trial: LIBERATE-1 Primary Objectives:
Slide 21: NPM-115 Clinical + Regulatory Development Near-Term Plan
NPM-115 Clinical + Regulatory Development Near-Term Plan
Slide 22: NPM-119 Exenatide Implant for Type 2 Diabetes
NPM-119 Exenatide Implant for Type 2 Diabetes
Slide 23: Development of a 6-Month Exenatide Implant for Type 2 Diabetes
Development of a 6-Month Exenatide (Glucagon-like Peptide 1 Receptor Agonist) Implant for Type 2 Diabetes
Slide 24: Current Drug Adherence Challenge
Current Drug Adherence Challenge "Drugs don't work in people that don't take them"
Slide 25: Patient research indicates strong adoption potential
Patient research indicates strong adoption potential for a miniature, 6-month exenatide implant
Slide 26: Prescriber and Payer research support miniature 6-month exenatide implant
Prescriber and Payer research also provide strong support for a miniature, 6-month exenatide implant
Slide 27: NPM-119 Clinical + Regulatory Development Near-Term Plan
NPM-119 Clinical + Regulatory Development Near-Term Plan
Slide 28: NPM-119 Clinical + Regulatory Development
NPM-119 Clinical + Regulatory Development Near-Term Plan 2024 INDcleared June 2024 June 13, 2024 - Vivani announced that the FDA cleared the NPM-119 IND to enable the evaluation of its exenatide implant in patients with type 2 diabetes. July 11, 2024 - Vivani reiterated its strategic shift to focus
Slide 29: Q3 2024: Income/(Loss) Statement
Vivani Medical, Inc. Q3 2024: Income/(Loss) Statement
Slide 30: Q3 2024: Balance Sheet
Vivani Medical, Inc. Q3 2024: Balance Sheet*
Slide 31: Q3 2024: Cap Table
Vivani Medical, Inc. Q3 2024: Cap Table
Slide 32: Vivani Medical overview
An innovative, biopharmaceutical company developing a portfolio of ultra long-acting, miniature, drug implants to treat chronic diseases. NanoPortal™ platform technology enables the design of implants aimed at improving medication non-adherence and tolerability.
Slide 33: Vivani Medical, Inc.
Vivani Medical, Inc. © CVOVS An innovative, biopharmaceutical company developing a portfolio of ultra long-acting, miniature, drug implants to treat chronic diseases. NanoPortal™ platform technology enables the design of ty. plants aimed at improving medication non-adherence and toleral Lead program